ArticlePloS one2018
Disease progression in mice exposed to low-doses of aerosolized clinical isolates of Burkholderia pseudomallei.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 21 citations in OpenAlex.
- Virulence of Burkholderia pseudomallei Strains from Western Hemisphere and Africa in Mice.Emerging infectious diseases · 2026Article
- Characterization of an isogenicInfection and immunity · 2026Article
- Buprenorphine extended-release (Ethiqa XR) impacts the immunological response in mice exposed to aerosolizedFrontiers in immunology · 2026Article
- Evaluation of a potent LpxC inhibitor for post-exposure prophylaxis treatment of antibiotic-resistantAntimicrobial agents and chemotherapy · 2025Article
- Nanolipoprotein particle (NLP) vaccine confers protection againstFrontiers in immunology · 2025Article
- Immune responses following DNA vaccination by needle-free injection againstFrontiers in immunology · 2025Article
- Comparison of homologous and heterologous vaccination strategies for combating disease caused byFrontiers in immunology · 2025Article
- Virulence of Burkholderia pseudomallei ATS2021 Unintentionally Imported to United States in Aromatherapy Spray.Emerging infectious diseases · 2024Article
- The BALB/c Mouse Model for the Evaluation of Therapies to Treat Infections with AerosolizedAntibiotics (Basel, Switzerland) · 2023Article
- Efficacy of Treatment with the Antibiotic Novobiocin against Infection withAntibiotics (Basel, Switzerland) · 2022Article
- Evaluation of two different vaccine platforms for immunization against melioidosis and glanders.Frontiers in microbiology · 2022Article
- Layered and integrated medical countermeasures againstFrontiers in microbiology · 2022Article
- Protection Elicited by Attenuated LiveVaccines · 2021Article
- Comparative virulence of three different strains of Burkholderia pseudomallei in an aerosol non-human primate model.PLoS neglected tropical diseases · 2021Article
- Activation of Toll-Like Receptors by Live Gram-Negative Bacterial Pathogens Reveals Mitigation of TLR4 Responses and Activation of TLR5 by Flagella.Frontiers in cellular and infection microbiology · 2021Article
- Impact of Toll-Like Receptor-Specific Agonists on the Host Immune Response to theFrontiers in immunology · 2021Article
- Laser Scanning Confocal Microscopy Was Used to Validate the Presence ofTropical medicine and infectious disease · 2020Article
- The Impact of Age and Sex on Mouse Models of Melioidosis.Pathogens (Basel, Switzerland) · 2020Article
- Article
- Deletion of Two Genes inVaccines · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mouse models have been essential to generate supporting data for the research of infectious diseases. Burkholderia pseudomallei, the etiological agent of melioidosis, has been studied using mouse models to investigate pathogenesis and efficacy of novel medical countermeasures to include both vaccines and therapeutics. Previous characterization of mouse models of melioidosis have demonstrated that BALB/c mice present with an acute infection, whereas C57BL/6 mice have shown a tendency to be more resistant to infection and may model chronic disease. In this study, either BALB/c or C57BL/6 mice were exposed to aerosolized human clinical isolates of B. pseudomallei. The bacterial strains included HBPUB10134a (virulent isolate from Thailand), MSHR5855 (virulent isolate from Australia), and 1106a (relatively attenuated isolate from Thailand). The LD50 values were calculated and serial sample collections were performed in order to examine the bacterial burdens in tissues, histopathological features of disease, and the immune response mounted by the mice after exposure to aerosolized B. pseudomallei. These data will be important when utilizing these models for testing novel medical countermeasures. Additionally, by comparing highly virulent strains with attenuated isolates, we hope to better understand the complex disease pathogenesis associated with this bacterium.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.